Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20137822rdf:typepubmed:Citationlld:pubmed
pubmed-article:20137822lifeskim:mentionsumls-concept:C0206698lld:lifeskim
pubmed-article:20137822lifeskim:mentionsumls-concept:C0021701lld:lifeskim
pubmed-article:20137822lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:20137822lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:20137822lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:20137822lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:20137822pubmed:issue3lld:pubmed
pubmed-article:20137822pubmed:dateCreated2010-3-2lld:pubmed
pubmed-article:20137822pubmed:abstractTextHepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are common primary hepatic malignancies. Their immunohistological differentiation using specific markers is pivotal for treatment and prognosis. We found alphavbeta6 integrin strongly upregulated in biliary fibrosis, but its expression in primary and secondary liver tumours is unknown. Here, we aimed to evaluate the diagnostic applicability of alphavbeta6 integrin in differentiating primary liver cancers.lld:pubmed
pubmed-article:20137822pubmed:languageenglld:pubmed
pubmed-article:20137822pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20137822pubmed:citationSubsetIMlld:pubmed
pubmed-article:20137822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20137822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20137822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20137822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20137822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20137822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20137822pubmed:statusMEDLINElld:pubmed
pubmed-article:20137822pubmed:monthMarlld:pubmed
pubmed-article:20137822pubmed:issn0168-8278lld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:ZimmermannAAlld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:EiseltBBlld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:KeoghAAlld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:WilkensLLlld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:StrokaDDlld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:StickelFFlld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:WeimannRRlld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:OsterreicherC...lld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:PatsenkerEElld:pubmed
pubmed-article:20137822pubmed:authorpubmed-author:BanzVVlld:pubmed
pubmed-article:20137822pubmed:copyrightInfoCopyright (c) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.lld:pubmed
pubmed-article:20137822pubmed:issnTypePrintlld:pubmed
pubmed-article:20137822pubmed:volume52lld:pubmed
pubmed-article:20137822pubmed:ownerNLMlld:pubmed
pubmed-article:20137822pubmed:authorsCompleteYlld:pubmed
pubmed-article:20137822pubmed:pagination362-9lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:meshHeadingpubmed-meshheading:20137822...lld:pubmed
pubmed-article:20137822pubmed:year2010lld:pubmed
pubmed-article:20137822pubmed:articleTitleThe alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.lld:pubmed
pubmed-article:20137822pubmed:affiliationInstitute of Clinical Pharmacology and Visceral Research, University of Bern, Murtenstrasse 35, Bern, Switzerland.lld:pubmed
pubmed-article:20137822pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20137822pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed